Deverra Therapeutics

Seeking Remission For All

Print
Claim My Business
Min Investment
$500
Location
Seattle, WA
Expected Close Date
April 29, 2024
Target Raise
$15.00K-$1.24M
Security Price
$2.09
Website
deverratx.com
Number of Employees
12
Cash
$78,636
Revenue
$0
Short Term Debt
$7,448,108
Cost of Goods
$6,678,838
Long Term Debt
$256,667
Net Income
$-6,899,704

Company Description

Deverra is a clinical-stage biotech company committed to providing universal donor treatments, opening doors for accessible & affordable immune cell therapies for cancer & other life-threatening illnesses.

Key Deal Facts

Deverra’s pioneering technology aims to reinvent the way immune cell therapies are developed & delivered. Our cell therapies are cost effective, safe & can be readily available – striving to make remission a reality for all patients.

Dilanubicel, Deverra’s lead clinical asset, has shown significantly improved remission rates in a phase 2 leukemia clinical trial with 184 patient infusions. Now, we’re just one clinical trial away from potential FDA approval.
Amount Raised : $649,656
Reveal the Score by Voting
_
Additional ratings from other users are needed to determine a viable CrowdScore for this deal.
The "CrowdScore" for this deal is determined by user ratings and other factors using our proprietary algorithm.
The overall viability and scalability of the business concept as well as the ability to drive the concept to profitability over time.
Business Idea
The progress made thus far in demonstrating that the business has viability, a customer base or other business traction.
Business Traction
The experience of the management team in running, scaling and/or exiting a business that required similar skills to execute the business plan.
Management Team
The value of the company compared to similar companies raising money from investors.
Valuation

Research Reports

No reports have been submitted

Become a Reporter

0 Comments